News

Editor's picks

Some children with congenital adrenal hyperplasia (CAH) could benefit from treatment with the aromatase inhibitor anastrozole to optimise their growth potential, US researchers suggest.
A study of infant girls has characterised the hormonal changes of minipuberty and uncovered how the ovaries, uterus and reproductive hormones interrelate during this period.
Use of the glucagon-like peptide -1 receptor agonist liraglutide alongside diet and exercise guidance significantly reduces BMI in children aged 6 to 11 years with severe obesity compared with lifestyle interventions alone, shows the SCALE Kids Trial.

Latest headlines

Some children with congenital adrenal hyperplasia (CAH) could benefit from treatment with the aromatase inhibitor anastrozole to optimise their growth potential, US researchers suggest.
Once daily oral treatment with infigratinib has a tolerable side effect profile and a significant positive benefit on both annualised height velocity and upper-to-lower body segment ratio in children with achondroplasia, indicates research published in The New England Journal of Medicine.
A study of infant girls has characterised the hormonal changes of minipuberty and uncovered how the ovaries, uterus and reproductive hormones interrelate during this period.
Researchers have identified novel pathogenic variants that may account for approximately 9% of children with Silver–Russell syndrome who have not previously had a molecular diagnosis and aid understanding of the relationships between genotype and phenotype.
Use of the glucagon-like peptide -1 receptor agonist liraglutide alongside diet and exercise guidance significantly reduces BMI in children aged 6 to 11 years with severe obesity compared with lifestyle interventions alone, shows the SCALE Kids Trial.
One-year findings from the REAL5 trial show a continued growth response with use of long-acting human growth hormone treatment with somapacitan at a dose of 0.24 mg/kg per week in children born small for gestational age.
Phase 3 trial findings support the use of an oral corticotropin-releasing factor type 1 receptor antagonist for the treatment of classic congenital adrenal hyperplasia in children with 21-hydroxylase deficiency.
Radioactive iodine therapy may be avoided for some children undergoing surgery for papillary thyroid carcinoma, suggest findings from a study that shows good outcomes even for those with cervical lymph node metastases.
Central congenital hypothyroidism is frequently missed in Israeli infants despite a newborn screening programme for thyroid dysfunction, shows research published in the Journal of Clinical Endocrinology & Metabolism.
Researchers have characterised the pathogenesis, prognosis, treatment, neurological sequelae and prevalence of congenital hyperinsulinism in children born in Norway, finding genetic alterations to ABCC8 to be the most common cause of the condition.
Italian researchers have determined a glucagon stimulation test threshold that can predict whether a teenager with growth hormone deficiency has or has not experienced normalisation of GH levels at the time of transition to adult care.
Dutch research indicates that health-related quality of life remains largely stable over the 12 years after completion of growth hormone therapy for short stature in children who were born small for gestational age.
Martin Savage
Programme Director
Sign up for eAlerts
Be the first to hear about new resources and content by signing up to receive our eAlerts.